title: Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis.
abstract: BACKGROUND
  It is unclear whether S-1 plus cisplatin is effective for patients with recurrent gastric cancer after adjuvant S-1 chemotherapy.
  
  
  METHODS
  We retrospectively evaluated the efficacy of S-1 plus cisplatin in patients whose gastric cancer recurred after adjuvant S-1 chemotherapy.
  
  
  RESULTS
  In the 52 patients evaluated, the median duration of adjuvant S-1 chemotherapy was 8.1 months, and the median recurrence-free interval (RFI) since the last administration of adjuvant S-1 was 6.4 months. Among the 36 patients with measurable lesions, 7 achieved a complete or partial response, and 13 were evaluated as having stable disease, for an overall response rate of 19.4% and a disease control rate of 55.6%. For all patients, the median progression-free survival (PFS) was 4.8 months, and the median overall survival (OS) was 12.2 months. Compared with patients with an RFI of <6 months (n = 25), patients with an RFI of ≥6 months (n = 27) had a significantly higher response rate (5.0 vs. 37.5%, respectively), longer PFS (2.3 vs. 6.2 months, respectively), and longer overall survival (7.3 vs. 16.6 months, respectively). According to a multivariate Cox model including performance status (PS) and reason for discontinuation of adjuvant S-1, an RFI of 6 months was still significantly associated with PFS and OS.
  
  
  CONCLUSIONS
  S-1 plus cisplatin is effective for patients with gastric cancer that recurs after adjuvant S-1 chemotherapy, especially for those with an RFI of ≥6 months.
authors: Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan. Kouheis0824@yahoo.co.jp
authors: Kohei
authors: K
authors: Shitara
authors: Satoshi
authors: S
authors: Morita
authors: Kazumasa
authors: K
authors: Fujitani
authors: Shigenori
authors: S
authors: Kadowaki
authors: Nobuhiro
authors: N
authors: Takiguchi
authors: Naoki
authors: N
authors: Hirabayashi
authors: Masazumi
authors: M
authors: Takahashi
authors: Masakazu
authors: M
authors: Takagi
authors: Yukihiko
authors: Y
authors: Tokunaga
authors: Ryoji
authors: R
authors: Fukushima
authors: Yasuhiro
authors: Y
authors: Munakata
authors: Kazuhiro
authors: K
authors: Nishikawa
authors: Akinori
authors: A
authors: Takagane
authors: Takaho
authors: T
authors: Tanaka
authors: Yoshiaki
authors: Y
authors: Sekishita
authors: Junichi
authors: J
authors: Sakamoto
authors: Akira
authors: A
authors: Tsuburaya
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000209:etiology; D010094:Oxonic Acid / Q000008:administration & dosage; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin